Lilly's pre-launch stockpile of the obesity pill reaches about $1.5 billion

Eli Lilly had built up $1.5 billion worth of pre-launch inventory of its experimental obesity pill orforglipron as of Dec. 31, according to a securities filing made public this week ^[1][2]. That is nearly triple the roughly $550 million in pre-launch inventory the company reported a year earlier, in February 2025 ^[1][2]. Most of the current inventory is tied to orforglipron, which is not yet approved in the United States ^[2].

The buildup comes ahead of an expected U.S. Food and Drug Administration decision on the drug, with a target date of April 10, 2026 ^[2]. Orforglipron received an FDA Commissioner's National Priority Voucher last November, a program meant to speed reviews for products tied to national health priorities, with a potential review window of one to two months instead of the typical 10 to 12 months for most new medicines ^[1][2]. Despite that expedited pathway, the FDA pushed the target decision date to April, according to Reuters and other outlets ^[2].

Lilly executives have said they intend to launch broadly and quickly if approval comes through. Daniel Skovronsky, the company's chief scientist, said at the J.P. Morgan Healthcare Conference in January that Lilly planned to launch orforglipron "in many, many countries around the world, as quickly as possible" ^[1][2]. Lilly has also said separately that it is confident in its weight-loss pill supply ahead of a possible U.S. approval ^[1].

Analysts and trade press read the scale of the stockpile as a deliberate effort to avoid a repeat of the shortages that dogged Lilly's injectable GLP-1 drugs, Mounjaro and Zepbound, when they first launched ^[2]. Those early shortfalls helped fuel a market for compounded versions of GLP-1 medicines that has been difficult to regulate, even after Lilly and Novo Nordisk resolved their supply constraints ^[2]. Building up inventory before an approval is a common practice among drugmakers, and companies typically disclose these stockpiles in financial filings to show how much product has been manufactured in advance ^[1].

Orforglipron would launch into a market where Novo Nordisk's Wegovy pill, a semaglutide product, is already established. Novo's oral Wegovy launched in the U.S. in early January 2026, selling at $149 a month for self-pay patients, and prescriptions hit more than 26,000 in its second full week on the market, according to IQVIA data cited by an analyst ^[1]. Fierce Pharma reported that the Wegovy pill has been tracking prescription numbers that outpace the launches of earlier injectable GLP-1 drugs for weight loss ^[2].

Why it matters for patients

For people who might eventually take orforglipron, a large pre-launch stockpile could mean a smoother start than what happened with Mounjaro and Zepbound, where early shortages left some patients unable to fill prescriptions and pushed some toward compounded alternatives ^[2]. A bigger inventory does not guarantee steady long-term supply, but it suggests Lilly is trying to avoid the bottlenecks that shaped the early years of injectable GLP-1 drugs.

The pill would also enter a market that already has an oral option in Novo Nordisk's Wegovy pill, giving patients and prescribers a choice between competing oral GLP-1 products if orforglipron is approved ^[1][2]. Pricing for orforglipron itself is not addressed in these sources, so it is not yet known how its cost will compare with Novo's $149-a-month self-pay price for the Wegovy pill ^[1].

What happens next

The FDA's target decision date for orforglipron is April 10, 2026 ^[2]. If approved, Lilly has said it aims to launch the pill in multiple countries nearly simultaneously ^[1][2]. Whether the accelerated review under the National Priority Voucher program holds to that date, given the FDA's earlier delay from a one- to two-month window, is not yet known ^[2].